AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia

 AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia

AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ASCEND Study for R/R Chronic Lymphocytic Leukaemia

Shots:

  • The P-III ASCEND study involves assessing of Calquence (acalabrutinib, 100mg, q2d) vs Rituximab + Idelalisib/Bendamustine in 310 previously treated patients in a ratio (1:1) with CLL
  • The P-III ASCEND study resulted in meeting its 1EPs i.e, improvement in progression-free survival (PFS), increment in the time for the next treatment and is safe & tolerable
  • Calquence (acalabrutinib) is a BTK inhibitor, inhibiting its activity in B-cells, currently being evaluated in 26 studies by AstraZeneca & Acerta Pharma and has received FDA’s accelerated approval for MCL with one prior therapy in Oct’17  

Click here to read full press release/ article | Ref: AstraZeneca | Image: Touch concept

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post